GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (FRA:PSH0) » Definitions » Stock Based Compensation

Sernova Biotherapeutics (FRA:PSH0) Stock Based Compensation : €0.90 Mil (TTM As of Apr. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sernova Biotherapeutics Stock Based Compensation?

Sernova Biotherapeutics's Stock Based Compensation for the three months ended in Apr. 2025 was €0.35 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Apr. 2025 was €0.90 Mil.


Sernova Biotherapeutics Stock Based Compensation Historical Data

The historical data trend for Sernova Biotherapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Stock Based Compensation Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.15 5.53 2.70 1.17

Sernova Biotherapeutics Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.33 -0.27 0.49 0.35

Sernova Biotherapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.90 Mil.


Sernova Biotherapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

Sernova Biotherapeutics Headlines

No Headlines